Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: A meta-analysis

Blood

Volumn 107, Issue 7, 2006, Pages 2766-2773

  Dentali, Francesco ^b   Crowther, Mark ^a   Ageno, Walter ^b  

^a ST JOSEPH S HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; ORAL CONTRACEPTIVE AGENT; PROTHROMBIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN VEIN; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MANTEL HAENSZEL TEST; META ANALYSIS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOSIS;

EID: 33645510408     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-09-3578     Document Type: Article

References (52)

1. Ferro JM, Canhao P, Stam J, Bousser MG, Barinagarrementeria F; ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35:664-670.
2. Ameri A, Bousser MG. Cerebral venous thrombosis. Neurol Clin. 1992;10:87-111.
3. Gates PC. Cerebral venous thrombosis: a retrospective review. Aust N Z J Med. 1986;16:766-770.
4. De Bruijn SF, Stam J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke. 1999;30:484-488.
5. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993;90:1004-1008.
6. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature.1994;369:64- 67.
7. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
8. Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med. 1999;130:643-650.
9. Salomon O, Steinberg DM, Zivelin A, et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol. 1999;19:511-518.
10. Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism - pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost. 2001;86:809-816.
11. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995;346:1575-1582.
12. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344:1453-1457.
13. McGinn T, Wyer PC, Newman TB, Keitz S, Leipzig R, Guyatt G, for Evidence-Based Medicine Teaching Tips Working Group.Tips for learners of evidence-based medicine, 3: measures of observer variability (kappa statistic). CMAJ. 2004;171:1369-1373.
14. Maclure M, Willett WC. Misinterpretation and misuse of the kappa statistic. Am J Epidemiol. 1987;126:161-169.
15. Stroup DF, Berlin JA, Morton SC, et al. Metaanalysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-2012.
16. Hayden GF, Kramer MS, Horwitz RI. The case-control study: a practical review for the clinician. JAMA. 1982;247:326-331.
17. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-748.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
20. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323:101-105.
21. Cantu C, Alonso E, Jara A, et al. Hyperhomocysteinemia, low folate and vitamin B12 concentrations, and methylene tetrahydrofolate reductase mutation in cerebral venous thrombosis. Stroke. 2004;35:1790-1794.
22. Ventura P, Cobelli M, Marietta M, Panini R, Rosa MC, Salvioli G. Hyperhomocysteinemia and other newly recognized inherited coagulation disorders (factor V Leiden and prothrombin gene mutation) in patients with idiopathic cerebral vein thrombosis. Cerebrovasc Dis. 2004;17:153-159.
23. Martinelli I, Battaglioli T, Pedotti P, Cattaneo M, Mannucci PM. Hyperhomocysteinemia in cerebral vein thrombosis. Blood. 2003;102:1363-1366.
24. Bombeli T, Basic A, Fehr J. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems. Am J Hematol. 2002;70:126-132.
25. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med. 1998;338:1793-1797.
26. Weih M, Vetter B, Ziemer S, et al. Increased rate of factor V Leiden mutation in patients with cerebral venous thrombosis. J Neurol. 1998;245:149-152.
27. Delport R, Ubbink JB, Vermaak WJ, Rossouw H, Becker PJ, Joubert J. Hyperhomocysteinaemia in black patients with cerebral thrombosis. QJM. 1997;90:635-639.
28. Martinelli I, Rosendaal FR, Vandenbroucke JP, Mannucci PM. Oral contraceptives are a risk factor for cerebral vein thrombosis. Thromb Haemost. 1996;76:477-478.
29. Gadelha T, Andre C, Juca AA, Nucci M. Prothrombin 20210A and oral contraceptive use as risk factors for cerebral venous thrombosis. Cerebrovasc Dis. 2005;19:49-52.
30. Rodrigues CA, Rocha LK, Morelli VM, Franco RF, Lourenco DM. Prothrombin G20210A mutation, and not factor V Leiden mutation, is a risk factor for cerebral venous thrombosis in Brazilian patients. J Thromb Haemost. 2004;2:1211-1212.
31. Boncoraglio G, Carriero MR, Chiapparini L, et al. Hyperhomocysteinemia and other thrombophilic risk factors in 26 patients with cerebral venous thrombosis. Eur J Neurol. 2004;11:405-409.
32. Meng Q, Pu C. [Cerebral venous thrombosis and factor V Leiden mutation.] Zhonghua Yi Xue Za Zhi. 2002;82:47-49.
33. Marietta M, Bertesi M, Simoni L, Castelli I, Cappi C, Torelli G. Cerebral vein thrombosis and lupus anticoagulant antibodies. Clin Appl Thromb Hemost. 2001;7:238.
34. Madonna P, De Stefano V, Coppola A, Albisinni R, Cerbone AM. G20210A PRTH gene mutation and other thrombophilic polymorphisms in patients with cerebral vein thrombosis. Stroke. 2000;31:1787-1788.
35. Voetsch B, Damasceno BP, Camargo EC, et al. Inherited thrombophilia as a risk factor for the development of ischemic stroke in young adults. Thromb Haemost. 2000;83:229-233.
36. Weih M, Vetter B, Castell S, Ziemer S, Kulozik AE, Einhaupl KM. Hereditary thrombophilia in cerebral venous thrombosis. Cerebrovasc Dis. 2000;10:161-162.
37. Christopher R, Nagaraja D, Dixit NS, Narayanan CP. Anticardiolipin antibodies: a study in cerebral venous thrombosis. Acta Neurol Scand. 1999;99:121-124.
38. Ludemann P, Nabavi DG, Junker R, et al. Factor V Leiden mutation is a risk factor for cerebral venous thrombosis: a case-control study of 55 patients. Stroke. 1998;29:2507-2510.
39. Reuner KH, Ruf A, Grau A, et al. Prothrombin gene G20210 - A transition is a risk factor for cerebral venous thrombosis. Stroke. 1998;29:1765-1769.
40. de Bruijn SF, Stam J, Vandenbroucke JP. Increased risk of cerebral venous sinus thrombosis with third-generation oral contraceptives. Cerebral Venous Sinus Thrombosis Study Group. Lancet. 1998;351:1404.
41. de Bruijn SF, Stam J, Koopman MM, Vandenbroucke JP. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and in [correction of who are] carriers of hereditary prothrombotic conditions. The Cerebral Venous Sinus Thrombosis Study Group. BMJ. 1998;316:589-592.
42. Scoditti U, Buccino GP, Pini M, Pattacini C, Mancia D. Risk of acute cerebrovascular events related to low oestrogen oral contraceptive treatment. Ital J Neurol Sci. 1998;19:15-19.
43. Zuber M, Toulon P, Marnet L, Mas JL. Factor V Leiden mutation in cerebral venous thrombosis. Stroke. 1996;27:1721-1723.
44. Kimber TE, Lloyd JV, Brophy BP, Thompson PD. Cerebral venous sinus thrombosis associated with factor V gene mutation. J Neurol Neurosurg Psychiatry. 1996;61:204-205.
45. Martinelli I, Landi G, Merati G, Cella R, Tosetto A, Mannucci PM. Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost. 1996;75:393-394.
46. Margaglione M, Brancaccio V, Ciampa A, Papa ML, Grandone E, Di Minno G. Inherited thrombophilic risk factors in a large cohort of individuals referred to Italian thrombophilia centers: distinct roles in different clinical settings. Haematologica. 2001;86:634-639.
47. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995;346:1133-1134.
48. Price DT, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Intern Med. 1997;127:895-903.
49. Den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost. 1998;80:874-847.
50. College of American Pathologists Consensus Conference XXXVI: diagnostic issues in thrombophilia. Arch Pathol Lab Med. 2002;126:1277-1433.
51. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med. 2001;344:1222-1231.
52. Sutton AJ, Duval SJ, Tweedie RL, Abrams KR, Jones DR. Empirical assessment of effect of publication bias on meta-analyses. BMJ. 2000;320:1574-1577.